Pangen Signs Supply Contract for Biosimilar Products Worth 4 Billion KRW
[Asia Economy Reporter Minji Lee] PanGen announced on the 15th that it has signed a contract to supply the biosimilar Panfortin product to Junheon Pharmaceutical. The contract amount is approximately 423 million KRW, accounting for 15% of the total sales.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Was This Delicious Treat Enjoyed Only by Koreans?"... The K-Dessert Captivating Japan
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- People Power Party: "Jung Wonoh Spread GTX Railway Rumors... Filed Complaint for Dissemination of False Information"
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
